SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.

Discovery VIRUS COVID-19 Registry

A global COVID-19 registry that tracks ICU and hospital care patterns in near real time

visual bubble
visual bubble
visual bubble
visual bubble

Viral Infection and Respiratory Illness Universal Study (VIRUS) is a prospective, cross-sectional, observational study and registry of all eligible adult and pediatric patients who are admitted to a hospital. There is no intervention or patient interaction. Only de-identified data are used for analysis.

ClinicalTrials.gov Identifier: NCT04323787

VIRUS COVID-19 Registry Dashboard

 

SCCM




 
                  

VIRUS COVID-19 Registry Enrollment

Please check whether your site is already enrolled as a VIRUS participating site before enrolling. Then complete the intake form and download the frequently asked questions.

Check the VIRUS Participation List
Complete the Intake Form to Participate
Download VIRUS FAQs
 

Inclusion Criteria

  • COVID-19 PCR (or other SARS-CoV-2) test positive within 21 days
  • COVID-19 PCR pending
  • COVID-19 high clinical suspicion

Primary Aims

  • Create a real-time COVID-19 registry of current intensive care unit and hospital care patterns to allow evaluation of safety and observational effectiveness of COVID-19 practices
  • Determine practice variations across hospitals

Hypothesis

The registry will be essential for near-real-time observational comparative effectiveness studies to determine effective treatment strategies and/or provide meaningful hypotheses for clinical trials.


Institutional Review Board: Waiver of Consent

A waiver of informed consent for data collection is being requested for this study from participating sites. No patients will be contacted, but clinicians participating in the study will be surveyed for feedback and satisfaction. For any questions, contact Vishakha Kumar.
 

Join the SCCM Connect Discovery Group

Approved sites with IRB approval can join the SCCM Connect Discovery Group. Access includes a discussion board and the ability to connect with other Discovery participants.

This is the best way to get regular updates about VIRUS!

Request to join the Discovery SCCM Connect Group
 

STOP-VIRUS ICU Learning Collaborative

ICUs participating in the VIRUS Registry may also be among the 20 sites participating in the STOP-VIRUS collaborative. For more information about this network of ICUs, its leaders and participants, and the learning material being developed, click here.


Recent Publications

Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group
Garcia MA, Johnson SW, Bosch NA, Sisson EK, Sheldrick CR, Kumar VK, Boman K, Bolesta S, Bansal V, Deo N, Domecq JP, Lal A, Christie AB, Banner-Goodspeed VM, Sanghavi D, Vadgaonkar G, Gajic O, Kashyap R, Walkey AJ. Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. Crit Care Explor. 2021 Nov 2;3(11):e0566.
Program Type: VIRUS DISCOVERY

Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry
Amer M, Kamel AM, Bawazeer M, Maghrabi K, Butt A, Dahhan T, Kseibi E, Khurshid SM, Abujazar M, Alghunaim R, Rabee M, Abualkhair M, Al-Janoubi A, AlFirm AT, Gajic O, Walkey AJ, Mosier JM, Zabolotskikh IB, Gavidia OY, Teruel SY, Bernstein MA, Boman K, Kumar VK, Bansal V, Kashyap R; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. Eur J Med Res. 2021 Oct 2;26(1):117.
Program Type: VIRUS DISCOVERY

Risk Factors for Critical Coronavirus Disease 2019 and Mortality in Hospitalized Young Adults: An Analysis of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) Coronavirus Disease 2019 Registry
Tripathi S, Sayed IA, Dapul H, McGarvey JS, Bandy JA, Boman K, Kumar VK, Bansal V, Retford L, Cheruku S, Kaufman M, Heavner SF, Danesh VC, St Hill CA, Khanna AK, Bhalala U, Kashyap R, Gajic O, Walkey AJ, Gist KM. Risk Factors for Critical Coronavirus Disease 2019 and Mortality in Hospitalized Young Adults: An Analysis of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) Coronavirus Disease 2019 Registry. Crit Care Explor. 2021 Aug 20;3(8):e0514.
Program Type: VIRUS DISCOVERY

Characterization and Outcomes of Hospitalized Children With Coronavirus Disease 2019: A Report From a Multicenter, Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) Registry
Bhalala US, Gist KM, Tripathi S, Boman K, Kumar VK, Retford L, Chiotos K, Blatz AM, Dapul H, Verma S, Sayed IA, Gharpure VP, Bjornstad E, Tofil N, Irby K, Sanders RC Jr, Heneghan JA, Thomas M, Gupta MK, Oulds FE, Arteaga GM, Levy ER, Gupta N, Kaufman M, Abdelaty A, Shlomovich M, Medar SS, Iqbal O'Meara AM, Kuehne J, Menon S, Khandhar PB, Miller AS, Barry SM, Danesh VC, Khanna AK, Zammit K, Stulce C, McGonagill PW, Bercow A, Amzuta IG, Gupta S, Almazyad MA, Pierre L, Sendi P, Ishaque S, Anderson HL 3rd, Nawathe P, Akhter M, Lyons PG, Chen C, Walkey AJ, Bihorac A, Wada Bello I, Ben Ari J, Kovacevic T, Bansal V, Brinton JT, Zimmerman JJ, Kashyap R; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Characterization and Outcomes of Hospitalized Children With Coronavirus Disease 2019: A Report From a Multicenter, Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) Registry. Crit Care Med. 2021 Aug 16.
Program Type: VIRUS DISCOVERY

The Impact of Obesity on Disease Severity and Outcomes Among Hospitalized Children with COVID-19
Tripathi S, Christison AL, Levy E, McGravery J, Tekin A, Bolliger D, Kumar VK, Bansal V, Chiotos K, Gist KM, Dapul HR, Bhalala US, Gharpure VP, Heneghan JA, Gupta N, Bjornstad EC, Montgomery VL, Walkey A, Kashyap R, Arteaga GM. The Impact of Obesity on Disease Severity and Outcomes Among Hospitalized Children with COVID-19. Hosp Pediatr. 2021 Jun 24:e2021006087. doi: 10.1542/hpeds.2021-006087. 
Program Type: VIRUS DISCOVERY

visual bubble
visual bubble
visual bubble
visual bubble
visual bubble

VIRUS Investigators 

Discovery, the Critical Care Research Network, is leading the efforts for this global COVID-19 registry. 
Rahul Kashyap, MBA, MD
VIRUS Principal Investigator
Rahul Kashyap, MBA, MD

HCA Healthcare
Nashville, Tennessee, USA
Mayo Clinic
Rochester, Minnesota, USA

Allan J. Walkey, MD, MSc
VIRUS Co-Principal Investigator
Allan J. Walkey, MD, MSc

Boston University
Boston, Massachusettes, USA

Juan Pablo Domecq Garces, MD
VIRUS Co-Principal Investigator
Juan Pablo Domecq Garces, MD

Mayo Clinic Foundation
Rochester, Minnesota, USA

Vishakha Kumar, MD, MBA
VIRUS Co-Principal Investigator
Vishakha Kumar, MD, MBA

Discovery, the Critical Care Research Network
Society of Critical Care Medicine


VIRUS Ancillary Studies

Ancillary study proposals may be submitted for a subset of de-identified data for research purposes by investigators of participating sites in the VIRUS study. 

The proposal submission period is now closed.
 

Information for Investigators

  • Any conflict of interest with the ancillary study proposal will be disclosed by the reviewers and the investigators.
  • The ancillary study proposals have been kept blinded from the VIRUS core investigator group. The first batch of ancillary proposals will be published once the review period closes and notifications are sent to the investigators.
  • SCCM, including the VIRUS core investigators group, has the first right upon publication of the dataset for the research hypothesis outlined for the VIRUS Study.
  • Study participants can serve on the writing group with the VIRUS core investigators team, if their ancillary study ideas overlap or align with the VIRUS overall project aims.
  • Collaboration (national and international) on ancillary proposal submissions is encouraged.
  • Ancillary proposal approval and data sharing will also depend on data quality and completion of the investigator’s own site data for the VIRUS study.

Ancillary Study Approval Process

Manuscript Approval Process